Clinical analysis of kasabach-merritt syndrome in 17 neonates
© Wang et al.; licensee BioMed Central Ltd. 2014
Received: 8 November 2013
Accepted: 29 May 2014
Published: 11 June 2014
Kasabach-Merritt syndrome (KMS) is characterized by giant hemangiomas and severe thrombocytopenia, which may result in life-threatening multi-organ hemorrhage. This study evaluated the clinical characteristics, treatments, and outcomes in neonates with KMS, in order to find out the optimal therapy.
The clinical data of 17 patients treated for KMS in the Department of Neonates, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, China from January 2007 to January 2012 were retrospectively analyzed.
The patients were 13 males and 4 females, aged 17 hours to 28 days at admission. Four patients had visceral hemangiomas and 13 had cutaneous hemangiomas. All had thrombocytopenia and coagulation disorders. Intravenous steroid therapy was initially effective in 6 patients (of which 3 relapsed) and ineffective in 11. The 11 patients with a poor response to steroids and the 3 who relapsed underwent arterial embolization therapy, which was effective in 9 patients (of which 1 relapsed), ineffective in 4, and discontinued before completion in 1. Subsequently, four patients in whom arterial embolization therapy was ineffective and one with relapse were treated with vincristine. This was effective in four patients, and the other died of disseminated intravascular coagulation. Steroid therapy was effective in 35.3% of patients, but the relapse rate was 50%. Arterial embolization was effective in 64.3% of patients and vincristine was effective in 80%.
In patients with neonatal KMS, steroid therapy has a low rate of effectiveness and high rate of relapse. Arterial embolization has a good rate of effectiveness. Combined steroid and embolization therapy should be considered for first-line treatment of neonatal KMS. If this approach is ineffective, vincristine may be useful.
KeywordsArterial embolization Steroid therapy Kasabach-Merritt syndrome Neonate Vincristine
Kasabach-Merritt syndrome (KMS), also known as giant hemangioma with thrombocytopenia, was first reported by Kasabach and Merritt in 1940. KMS accounts for about 1% of cases of hemangioma. KMS is characterized by giant hemangiomas and severe thrombocytopenia, which may result in life-threatening multi-organ hemorrhage. About 80% of patients present within 1 year after birth, and the reported mortality rate ranges from 10% to 37% . However, the optimal therapy for neonatal KMS is currently unclear. From January 2007 to January 2012, 17 patients with KMS were admitted to the Department of Neonates at Guangzhou Women and Children’s Medical Center in China.
From January 2007 to January 2012, 17 patients with giant hemangioma who were eventually diagnosed with KMS were admitted to the Department of Neonates at Guangzhou Women and Children’s Medical Center, China.
The diagnostic criteria for KMS were as follows: (1) hemangioma of the skin or internal organs; (2) thrombocytopenia and consumptive coagulopathy; (3) hemangioma confirmed by B-mode ultrasonography, color Doppler flow imaging, computed tomography (CT), or magnetic resonance imaging (MRI); (4) other causes for the abnormalities excluded, such as hypersplenism or idiopathic thrombocytopenic purpura.
The diagnostic criteria of DIC by ISTH
Overt DIC by ISTH
50,000 ~ 100,000/ul
Prolongation of PT
3 ~ 6 sec
> 6 sec
< 100 mg/dl
0.5 – 1
1 – 2
> = 2(μg/ml)
Overt DIC > =5 points
Written informed consents were obtained from the patients for publication of this case report and any accompanying image. Copies of the written consents are available for review by the Editor of this journal.
The research has been approved by Guangzhou Women and Children’s Medical Center’s appropriate ethics committee.
The appearances, characteristics, and complications of hemangioma in the 17 neonates with KMS were summarized and analyzed.
The 17 neonates with KMS were treated with steroid therapy, arterial embolization, and vincristine, depending on their individual responses to treatment.
The 17 patients with KMS included 13 males and 4 females. Their age at admission ranged from 17 hours to 28 days. One patient was born prematurely (34+5 weeks gestation), and the remainder were born at term. The birth weight ranged from 2300 g to 4000 g.
Laboratory examination findings
Laboratory examination findings showed a mean platelet count of 31.1 ± 21.7 × 109/L (range 2–119 × 109/L), hemoglobin concentration of 94.1 ± 21.1 g/L (range 66–128 g/L), prothrombin time of 28 ± 5.6 s (range 13–38 s) with a prolonged prothrombin time in 15 patients, thrombin time of 18 ± 3.6 s (range 15–28 s) with a prolonged thrombin time in 5 patients, activated partial thromboplastin time of 51 ± 5.8 s (range 40–72 s) with a prolonged activated partial thromboplastin time in 8 patients, and fibrinogen level of 0.8 ± 0.37 mg/dL (range 0.34-1.8 mg/dL) with a low fibrinogen level in 15 patients. Two patients met the diagnostic criteria for DIC.
The 17 patients received sequential combined therapy. The initial therapy was supportive. Six patients with a platelet count of <20 × 109/L received apheresis platelet infusions. Eight patients with a fibrinogen level of <1.0 mg/dL received cryoprecipitate infusions. Intravenous dexamethasone 1 mg/kg/day was administered simultaneously as first-line drug treatment. The platelet count started to increase at 3–8 days after the start of treatment in seven patients, reaching a normal value at 16–28 days. Coagulation function improved, and no bursting or bleeding of hemangiomas was observed. After the platelet count returned to normal, we evaluated the effectiveness of the therapeutic regimen. If the treatment was effective, it was gradually withdrawn over the following 1–2 months, after which patients were discharged on medication. The six patients who responded well to steroid therapy were regularly followed up at the hospital. In three patients, the platelet counts remained normal for the following year. The hemangiomas did not enlarge or bleed, and regressed within 1–2 years. In the other three patients, the platelet counts subsequently decreased (at 30 days, 3 months, and 5 months after treatment), and they were re-admitted to hospital and underwent arterial embolization. No relapses were observed over the following year.
The main diagnostic features of KMS are giant hemangioma and decreased platelet count. Giant cutaneous hemangiomas are easy to diagnose on physical examination. Visceral hemangiomas are easily missed, and patients may present with large ecchymoses. According to the cases in this research, it illustrates that KMS should be considered in children with unexplained thrombocytopenia and coagulation disorders. Routine blood testing showed varying degrees of low hemoglobin concentration, low plasma fibrinogen level, and prolonged prothrombin time. B-mode ultrasonography, CT, and MRI showed the size, appearance, and layers of hemangiomas, as well as their relationships with peripheral vessels, and distinguished hemangiomas from vascular malformations.
KMS is associated with Kaposi haemangioendothelioma(KHE) in over 90% of cases according to the research findings recently, and uncommonly with infantile and congenital haemangioma. The MRI findings of KHE have some characters. It presents as an enhancing, ill-defined, soft-tissue mass that is hypointense or isointense on T1 weighted images and hyperintense on T2 weighted images compared with muscle. Prominent vascular channels, presenting as flow voids in the tumour or as linear enhancing channels adjacent to the tumour, are usually noted . However, these findings are not specific for KHE. KHE can’t be confirmed by MRI only. The identification of hemangioma type rely mainly on pathologic examination, but KMS is associated with coagulation dysfunction, which is a contraindication of pathological biopsy. So our patients accepted B-mode ultrasonography, color Doppler flow imaging, or computed tomography (CT) because of the cheaper costs. Only one patient accepted MRI.
There are currently no consensus guidelines for the treatment of KMS. Some studies have reported good therapeutic effects with comprehensive sequential therapy, including steroid therapy, interferon, arterial embolization, vincristine, radiotherapy, and surgery [3–5]. There are no specific guidelines for diagnosis and treatment during the neonatal period.
In infants, glucocorticoid therapy is considered to be a good choice for initial drug treatment, because it can inhibit fibrinolysis and thrombosis, stimulate hematopoiesis in the bone marrow to increase release of platelets into the bloodstream, decrease the level of anti-platelet antibodies, and increase platelet count. However, it is only effective in 30% to 50% of patients with KMS [6, 7]. Glucocorticoid therapy may be administered orally, intravenously, or locally; and commonly starts to show effectiveness at 1–2 weeks after the onset of treatment . Our patients were treated with intravenous dexamethasone 1 mg/kg/day, and the platelet count started to increase after 3–8 days. In this study, steroid therapy was effective in 35.3% of patients, but the relapse rate was high (50%), resulting in an eventual effectiveness rate of only 17.6%. A more effective therapeutic approach is therefore necessary.
In patients who responded poorly to steroid therapy, arterial embolization was performed with bleomycin A5 (8–12 mg/m2), iodinated oil (2 mL), and dexamethasone (2 mg). Arterial embolization has been used to treat vascular tumors for many years [9, 10], and is useful for controlling symptoms and promoting regression of hemangiomas. However, neonates have tiny vessels, and do not tolerate such intervention well. There have been a few previous reports of treatment by arterial embolization in neonates with KMS in China, especially in patients with coagulation disorders. The dose of contrast agent needed, risk associated with general anesthesia, and difficulty in catheter placement limit the usefulness of this treatment in neonates. In the present study, arterial embolization was effective in 64.3% of patients. A previous study of arterial embolization using bleomycin A5 found that partial embolization significantly improved coagulation function and decreased hemangioma blood flow, and relieved symptoms . Another study found that local injection of urea destroyed the vascular endothelial cell matrix, suppressed endothelial cell growth, promoted endothelial cell atrophy, caused fibrosis of local tissue, hardened the tumor tissue, and caused thrombosis in the vascular lumen of the tumor body . Local injection of urea has been used to successfully treat hemangiomas and vascular malformations, and may be useful for the treatment of neonatal KMS . Arterial embolization in neonates is difficult and carries some risks, but can improve the patient’s condition if intravenous drug therapy has not controlled the hemangioma.
Intravenous vincristine has been used for the treatment of KMS, and can be used as a first-line drug in the treatment of Kaposiform hemangioendothelioma combined with KMS [13, 14]. An American multicenter study found that vincristine therapy was useful in patients who were resistant to steroid and interferon therapy [13, 15]. Vincristine, actinomycin, and cyclophosphamide can induce tumor regression and normalization of coagulation parameters . Although vincristine is neurotoxic, it can help to alleviate symptoms in patients with KMS. In this study, vincristine was administered to five patients who responded poorly to steroid therapy and arterial embolization, and was effective in 80% of these patients. No adverse effects related to chemotherapy were observed. These results indicate that vincristine can be used to treat neonatal KMS. However, this study only had a small number of subjects, and a larger sample is needed to confirm the effectiveness of vincristine therapy. Haisley-Royster et al.  reported that platelet counts in patients with KMS increased to normal values after 5 weeks of vincristine therapy. Vincristine therapy cannot avoid hemangioma relapse, but has been reported to result in prolonged reduction in hemangioma growth , which is consistent with the findings of this study.
It is worth noting that platelet transfusion is suitable for increasing the platelet count urgently or preoperatively, but it cannot be used routinely, because the hemangioma will consume the platelets [5, 17, 18]. Moreover, platelet transfusion will promote an increase in hemangioma size by inducing blood coagulation [5, 17, 18]. Excessive platelet transfusion has been reported to aggravate KMS [5, 17, 18]. In this study, patients received apheresis platelet transfusions if their platelet count was <20 × 109/L, which allowed us to perform arterial embolization. Transfusion therefore did not aggravate their condition.
Systemic interferon therapy has been used in patients who were resistant to steroid therapy, with good results [4, 18]. However, the effectiveness of interferon therapy is variable. Interferon therapy can be considered as a second-line drug treatment that is effective in 50% to 60% of patients, but it only has weak inhibitory effects on endothelial cell and vascular growth, and continuous treatment is needed . Continuous interferon therapy may result in increased transaminase levels, decreased platelet count, and decreased leukocyte count . A meta-analysis by Michaud et al.  found that interferon therapy could cause spastic diplegia and dyskinesia in infants. They recommended that interferon therapy should not be used in patients aged less than 1 year, except when other treatment methods are ineffective and the patient’s condition is life-threatening .
Leong et al.  reported two neonates with KMS who received radiotherapy after full-dose steroid therapy and α-interferon therapy were ineffective, resulting in a rapid increase in platelet count. The hemangioma gradually regressed over 3 years in one patient, and fully regressed within 2 months in the other patient. No adverse effects associated with radiotherapy were detected during the follow-up periods of 8 and 5 years, respectively, suggesting that radiotherapy may be a safe and effective treatment for KMS. However, another study reported that radiotherapy for hemangioma may increase the frequency of secondary tumors . The safety and effectiveness of radiotherapy for the treatment of KMS should be evaluated in further clinical studies with follow-up over a few decades.
Neonatal KMS has a high relapse rate after steroid therapy. Arterial embolization has a good rate of effectiveness. Combined steroid therapy and arterial embolization can be used as first-line treatment for neonatal KMS. If this combination is ineffective, vincristine therapy may be useful.
PW proposed the study and wrote the first draft. WZ guided the design of the study and helped to draft the manuscript. LT participated in its design and coordination and helped to revise the manuscript. NZ conceived of the study, and helped the acquisition and interpretation of data. XWC helped to draft the manuscript. All authors read and approved the final manuscript.
Ping Wang is the first author of this paper.
Magnetic resonance imaging
Disseminated intravascular coagulation
International Society on Thrombosis and Haemostasis
We thank Zhang Jing, Chen Kunshan, Zhou Shaoyi who provided acquisition of data service in Interventional Radiology Department of Guangzhou Women and Children’s Medical Center.
- Kwok-Williams M, Perez Z, Squire R, Glaser A, Bew S, Taylor R: Radiotherapy for life-threatening mediastinal haemangioma with kasabach-merritt syndrome. Pediatr Blood Cancer. 2007, 49: 739-744. 10.1002/pbc.20767.View ArticlePubMedGoogle Scholar
- Chen YJ, Wang CK, Tien YC, Hsieh TJ: MRI of multifocal kaposiform haemangioendothelioma without kasabach-merritt phenomenon. Br J Radiol. 2009, 82: e51-e54. 10.1259/bjr/16482217.View ArticlePubMedGoogle Scholar
- Lei H, Sui B, Liu D: Comprehensive sequential therapy of kasabach-merritt syndrome. Nat Med J China. 2011, 91: 2538-2541.Google Scholar
- Yoon HS, Lee JH, Moon HN, Seo JJ, Im HJ, Goo HW: Successful treatment of retroperitoneal infantile hemangioendothelioma with kasabach-merritt syndrome using steroid, α-interferon, and vincristine. J Pediatr Hematol Oncol. 2009, 31: 952-954. 10.1097/MPH.0b013e3181b7eb24.View ArticlePubMedGoogle Scholar
- Hauer J, Graubner U, Konstantopoulos N, Schmidt S, Pfluger T, Schmid I: Effective treatment of kaposiform hemangioendotheliomas associated with kasabach-merritt phenomenon using four-drug regimen. Pediatr Blood Cancer. 2007, 49: 852-854. 10.1002/pbc.20750.View ArticlePubMedGoogle Scholar
- Hesselmann S, Micke O, Marquardt T, Baas S, Bramswig JH, Harms E, Willich N: Case report: kasabach-merritt syndrome: a review of the therapeutic option and a case report of successful treatment with radiotherapy and interferon alpha. Br J Radiol. 2002, 75: 180-184. 10.1259/bjr.75.890.750180.View ArticlePubMedGoogle Scholar
- Taegyun K, Roh MR, Cho S, Chung KY: Kasabach-merritt syndrome arising from tufted angioma successfully treated with systemic corticosteroid. Ann Dermatol. 2010, 22: 426-430. 10.5021/ad.2010.22.4.426.View ArticleGoogle Scholar
- Michaud AP, Bauman NM, Burke DK, Manaligod JM, Smith RJ: Spastic diplegia and other motor disturbances in Infants receiving interferon-alpha. Laryngoscope. 2004, 114: 1231-1236. 10.1097/00005537-200407000-00017.View ArticlePubMedGoogle Scholar
- O’Regan GM, Irvine AD, Yao N, O’Marcaigh A, Sheridan-Pereira M, Phelan E, McDermott MB, Twomey A, Russell J, Watson R: Mediastinal and neck kaposiform hemangioendothelioma:report of three cases. Pediatr Dermatol. 2009, 26: 331-337. 10.1111/j.1525-1470.2009.00913.x.View ArticlePubMedGoogle Scholar
- Argenta LC, Bishop E, Cho KJ, Andrews AF, Coran AG: Complete resolution of life-threatening hemangioma by embolization and cortico-steroids. Plast Reconstr Surg. 1982, 70: 739-744. 10.1097/00006534-198212000-00015.View ArticlePubMedGoogle Scholar
- Garcia-Monaco R, Giachetti A, Peralta O, Napoli N, Lobos P, Gioseffi L, Mariani G: Kaposiform hemangioendothelioma with kasabach-merritt phenomenon: successful treatment with embolization and vincristine in two newborns. J Vasc Interv Radiol. 2012, 23: 417-422. 10.1016/j.jvir.2011.12.007.View ArticlePubMedGoogle Scholar
- Dong C, Ma Y: Urea interventional therapy for severe maxillofacial cavernous hemangioma. Chinese J Plastic Surg. 2004, 20: 316-317.Google Scholar
- Haisley-Royster C, Enjolras O, Frieden IJ, Garzon M, Lee M, Oranje A, de Laat PC, Madern GC, Gonzalez F, Frangoul H, Le Moine P, Prose NS, Adams DM: Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol. 2002, 24: 459-462. 10.1097/00043426-200208000-00010.View ArticlePubMedGoogle Scholar
- López V, Martí N, Pereda C, Martín JM, Ramón D, Mayordomo E, Jordá E: Successful management of kaposiform hemangioendothelioma with kasabach-merritt phenomenon using vincristine and ticlopidine. Pediatr Dermatol. 2009, 26: 365-366. 10.1111/j.1525-1470.2009.00923.x.View ArticlePubMedGoogle Scholar
- Abass K, Saad H, Kherala M, Abd-Elsayed AA: Successful treatment of kasabach—merritt syndrome with vincristine and surgery: a case report and review of literature. Cases J. 2008, 1: 9-10.1186/1757-1626-1-9.View ArticlePubMedPubMed CentralGoogle Scholar
- Hu B, Lachman R, Phillips J, Peng SK, Sieger L: Kasabaeh—merritt syndrome associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and aetinomycin D. J Pediatr Hematol Oncol. 1998, 20: 567-569. 10.1097/00043426-199811000-00012.View ArticlePubMedGoogle Scholar
- Phillips WG, Marsden JR: Kasabaeh-merritt syndrome exacerbated by platelet transfusion. J R Soc Med. 1993, 86: 231-232.PubMedPubMed CentralGoogle Scholar
- Peker E, Kirimi E, Tuncer O, Ceylan A, Oner AF: Brachial plexus paralysis due to giant cavernous hemangioma with kasabach-merritt syndrome: successful management with interferon alpha. Platelets. 2009, 20: 603-605. 10.3109/09537100903247790.View ArticlePubMedGoogle Scholar
- Sarkar M, Mulliken JB, Kozakewich HP, Robertson RL, Burrows PE: Thrombocytopenic coagulopathy (kasabach- merritt phenomenon)is associated with and not with kaposiform hemangioendothelioma common infantile hemangioma. Plast Reconstr Surg. 1997, 100: 1377-1386. 10.1097/00006534-199711000-00001.View ArticlePubMedGoogle Scholar
- Dubois J, Hershon L, Carmant L, Bélanger S, Leclerc JM, David M: Toxicity profile of interferon alpha-2b in children: a prospective evaluation. J Pediatr. 1999, 135: 782-785. 10.1016/S0022-3476(99)70104-6.View ArticlePubMedGoogle Scholar
- Leong E, Bydder S: Use of radiotherapy to treat life-threatening kasabach-merritt syndrome. J Med Imaging Radiation Oncol. 2009, 53: 87-91. 10.1111/j.1754-9485.2009.02042.x.View ArticleGoogle Scholar
- Lindberg S, Karlsson P, Arvidsson B, Holmberg E, Lunberg LM, Wallgren A: Cancer incidence after radiotheraphy for skin hemangiomas during infancy. Acta Oncol. 1995, 34: 735-740. 10.3109/02841869509127180.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2431/14/146/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.